Editing Oncolytics Biotech Inc.
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 15: | Line 15: | ||
|'''Area served''' US and Canada predominantly | |'''Area served''' US and Canada predominantly | ||
|- | |- | ||
|'''Product(s)''' | |'''Product(s)''' Palareorep ; Several Clinical Research ongoing | ||
|- | |- | ||
|'''Headquarters''' Calgary, Canada | |'''Headquarters''' Calgary, Canada | ||
Line 67: | Line 67: | ||
== Product<ref>https://pubmed.ncbi.nlm.nih.gov/25693885/</ref> == | == Product<ref>https://pubmed.ncbi.nlm.nih.gov/25693885/</ref> == | ||
Oncolytics’ core product is '''Pelareorep,''' a cutting-edge intravenously delivered immunotherapeutic agent aiming to treat solid tumours and hematological malignancies'''.''' Oncolytics Biotech. is testing Pelareorep as a potential treatment as the immune system has difficulty recognising and destroying malignant cancerous cells. It can be used alone or for more successful results, in combination with other chemotherapeutic drugs such as Paclitaxel | Oncolytics’ core product is '''Pelareorep,''' a cutting-edge intravenously delivered immunotherapeutic agent aiming to treat solid tumours and hematological malignancies'''.''' Oncolytics Biotech. is testing Pelareorep as a potential treatment as the immune system has difficulty recognising and destroying malignant cancerous cells. It can be used alone or for more successful results, in combination with other chemotherapeutic drugs such as Paclitaxel, or immunotherapies such as CAR T, targeting a large market audience. | ||
Cancer cells (tumour cells) are unique in comparison to other cells in the body as they can rapidly multiply due to their ability to carry out a cell signalling pathway, namely the '''RAS-activated pathway''' | Cancer cells (tumour cells) are unique in comparison to other cells in the body as they can rapidly multiply due to their ability to carry out a cell signalling pathway, namely the '''RAS-activated pathway'''. As a proprietary isolate of the naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus reovirus, Pelareorep can target this pathway. '''Reoviruses''' are a group of RNA double stranded viruses possessing the ability to recognise unique glycans on cancerous cells via the σ1R protein to allow immune system enhancement. The RAS-activated pathway required for Pelareorep to function is only present in cancerous cells, this includes some of the most common cancers such as lung and breast cancer. | ||
Its mechanism of action involves the activation of both the innate and adaptive immune systems while weakening tumor defense mechanisms | Its mechanism of action involves the activation of both the innate and adaptive immune systems while weakening tumor defense mechanisms. This effect enhances the immune system's ability to combat cancer, rendering tumors more susceptible to a diverse range of oncology treatments. Pelareorep is injected intravenously, once it interacts with a RAS-activated cancer cells it rapidly multiplies which causes: | ||
* Release of cytokines (innate) | * Release of cytokines (innate) | ||
* Activation of Natural Killer cells (innate) | * Activation of Natural Killer cells (innate) | ||
* Dendritic cell activation (innate) | * Dendritic cell activation (innate) | ||
* '''T cell education and activation''' | * '''T cell education and activation''' (adaptive) | ||
* Tumour cell lysis | * Tumour cell lysis | ||
* Activation of the interferon-gamma (IFN-γ) signalling pathway | * Activation of the interferon-gamma (IFN-γ) signalling pathway | ||
After the cell has burst all of the daughter Pelareorep cells are released to continue the process in surrounding cancer cells with the same glycans, until all cancerous cells have been defeated. | After the cell has burst all of the daughter Pelareorep cells are released to continue the process in surrounding cancer cells with the same glycans, until all cancerous cells have been defeated. | ||
Pelareorep has been clinically tested in partnership with Canadian Cancer Trials Group for pancreatic, breast, head, neck, prostate, lung, colorectal, bladder and ovarian cancers. Breast and pancreatic cancer tests have shown statistically significant results and have moved to Phase III clinical trials, on track for licence enabling studies. The clinical tests have also shown '''low death rates and less adverse side effects''' in comparison to chemotherapy. Side effects are: chills, fever, headache, cough, myalgia, runny nose, sore throat, fatigue, lymphopenia or neutropenia all for less than 6 hours. | Pelareorep has been clinically tested in partnership with Canadian Cancer Trials Group for pancreatic, breast, head, neck, prostate, lung, colorectal, bladder and ovarian cancers. Breast and pancreatic cancer tests have shown statistically significant results and have moved to Phase III clinical trials, on track for licence enabling studies. The clinical tests have also shown '''low death rates and less adverse side effects''' in comparison to chemotherapy. Side effects are: chills, fever, headache, cough, myalgia, runny nose, sore throat, fatigue, lymphopenia or neutropenia all for less than 6 hours. | ||
Line 92: | Line 90: | ||
* Selectively destroys tumour cells, not normal, healthy cells | * Selectively destroys tumour cells, not normal, healthy cells | ||
* It has a predictive biomarker- peripheral T-cell clonality | * It has a predictive biomarker- peripheral T-cell clonality | ||
Pelareorep is manufactured at a commercial scale under a commercial supply agreement with '''MilliporeSigma''' (formerly Sigma-Aldrich) | Pelareorep is manufactured at a commercial scale under a commercial supply agreement with '''MilliporeSigma''' (formerly Sigma-Aldrich). At the moment, Pelareorep is mainly supplied to Canada and the US, however the company is looking to expand to other countries with 17 pending patent applications. | ||
Currently the price of Pelareorep is unknown as it isn't officially a marketed drug, but it is likely to be equivalent to the price of Pfizer's Paclitaxel at '''$18 for a supply of 5 millilitres.''' | Currently the price of Pelareorep is unknown as it isn't officially a marketed drug, but it is likely to be equivalent to the price of Pfizer's Paclitaxel at '''$18 for a supply of 5 millilitres.''' | ||
Line 227: | Line 225: | ||
|- | |- | ||
|Unlevered Free Cash Flow | |Unlevered Free Cash Flow | ||
| | |14,851 | ||
| | |21,330 | ||
| | |19,107 | ||
| | |20,303 | ||
| | |5,839 | ||
| | |16,160 | ||
| | |18,505 | ||
| | |23,404 | ||
|13,507 | |13,507 | ||
|126,192 | |126,192 | ||
Line 256: | Line 254: | ||
| | | | ||
| | | | ||
| | |14,966 | ||
| | |15,872 | ||
| | |18,591 | ||
|9,937 | |9,937 | ||
|85,976 | |85,976 |